Change the future
with cell therapy
Our aim is to develop new cell therapies
using “hematopoietic stem cells”.
Hematopoietic stem cells (HSCs) are the stem cells that are the very source of blood.
Our aim is to develop new cell therapies in order to treat blood cancer,
intractable blood diseases and genetic disorders.
The development of new cell therapies in the fight against leukemia and other blood cancers and genetic disorders
We are working on the development of next-generation cell therapy products that will utilize the unique properties of umbilical cord blood and peripheral blood, by expanding them in large quantities.
Successful in-vitro expansion of functional hematopoietic stem cells
We have succeeded in developing technology for the mass propagation of functional HSCs with blood reconstruction ability. In addition, since the technology does not use animal-derived components such as albumin and cytokines, HSCs can be propagated in large quantities with high quality and at low cost.
A growing need for the application of HSCs in cell therapy
In addition to providing new therapeutic options for the HSC transplantation treatments that are being performed today, we are also working on applications in the field of gene therapy, which has seen much active development in recent years.
Collaborative Research Agreement with National Cancer Center Japan
Celaid will be speaking at the "KPMG Tech Innovator Competition in Japan 2023"
Collaborative Research Agreement with Knowledge Palette
Interviews with the winners of the "JAPAN VENTURE AWARDS" are now available
Celaid will be speaking at the "World Affairs Council of Pittsburgh".
Celaid Featured in "Nikkei BP Beyond Health" Article